Ixazomib Significantly Prolongs Progression-Free Survival in High-Risk Relapsed/refractory Myeloma Patients.

Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.